Bivalent boosters target two viral strains in the same vaccine. The updated booster contains Moderna’s original vaccine and a candidate vaccine that targets the Omicron variant.
The vaccine was generally well tolerated, the company said, with side effects similar to booster doses of the current vaccine.
The 50-microgram bivalent booster, called mRNA-1273.214, generated a stronger antibody response against Omicron than the original Moderna vaccine. Subvariants of Omicron are currently responsible for virtually all new cases of Covid-19 in the United States.
In April, Moderna announced its first bivalent Covid-19 booster candidate – which combined elements of the current vaccine with updates based on the beta variant – induced higher antibody responses against all variants of concern, including including Omicron, compared to the company. original Covid-19 booster injection.